A bifunctional compound for degrading BRAF via the ubiquitin-proteasome pathway.
Bifunctional compounds targeting BRAF for degradation via the ubiquitin-proteasome pathway offer a novel approach to treat inflammatory, autoimmune, and proliferative diseases by effectively degrading BRAF, improving upon existing therapeutic methods.
JP2026517764APending Publication Date: 2026-06-02NURIX THERAPEUTICS INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- NURIX THERAPEUTICS INC
- Filing Date
- 2024-04-26
- Publication Date
- 2026-06-02
Smart Images
Figure 2026517764000001_ABST
Abstract
This disclosure relates to a compound of formula (I) useful for ex vivo, in vitro, or in vivo degradation of BRAF via the ubiquitin proteolytic pathway. This disclosure also provides pharmaceutically acceptable compositions comprising the compound, as well as methods for using the composition in the treatment of various diseases, conditions, and / or disorders. (I)
Need to check novelty before this filing date? Find Prior Art